The Perspective of Therapeutic Antibody Marketing in Iran: Trend and Estimation by 2025
Background. Monoclonal antibodies with high efficiency and specificity are one of the best strategies to diagnose and treat a variety of diseases such as cancer, autoimmunity, and inflammatory diseases. The market for monoclonal therapeutic antibodies (MTAs) has grown dramatically in the past decade...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Advances in Pharmacological and Pharmaceutical Sciences |
| Online Access: | http://dx.doi.org/10.1155/2021/5569590 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832547772578922496 |
|---|---|
| author | Monireh Golpour Pouya Vatanpour Mina Amini Majid Saeedi Nasim Hafezi Alireza Rafiei |
| author_facet | Monireh Golpour Pouya Vatanpour Mina Amini Majid Saeedi Nasim Hafezi Alireza Rafiei |
| author_sort | Monireh Golpour |
| collection | DOAJ |
| description | Background. Monoclonal antibodies with high efficiency and specificity are one of the best strategies to diagnose and treat a variety of diseases such as cancer, autoimmunity, and inflammatory diseases. The market for monoclonal therapeutic antibodies (MTAs) has grown dramatically in the past decade. Objective. Given the importance of these issues, developing countries spend a high cost on importing or producing MTAs annually. This study intends to examine the market of monoclonal therapeutic antibodies in Iran and predict the future growth rate of this market using the obtained data. Methods. Data on the status of MTAs in the country (from 2008 to 2018) were obtained from the Food and Drug Deputy of Mazandaran University of Medical Sciences. The market status of MTAs was studied based on the dosage forms, application, and price. Then, the market outlook was predicted up to year 2025. Results. The results showed that 58.8% of all MTAs were humanized, and 86% of all antibody-based drugs were used to treat cancer. Sales of MTA-based medications will reach $454 million by 2025 and are projected to grow significantly in the future. Conclusion. Given the increasing technology of the production of MTAs and their use in targeted therapies worldwide, their consumption market in Iran is expected to grow significantly. |
| format | Article |
| id | doaj-art-453c3ebb11cb4dab80d7cf8e2c4d9bac |
| institution | Kabale University |
| issn | 2633-4690 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Pharmacological and Pharmaceutical Sciences |
| spelling | doaj-art-453c3ebb11cb4dab80d7cf8e2c4d9bac2025-02-03T06:43:29ZengWileyAdvances in Pharmacological and Pharmaceutical Sciences2633-46902021-01-01202110.1155/2021/55695905569590The Perspective of Therapeutic Antibody Marketing in Iran: Trend and Estimation by 2025Monireh Golpour0Pouya Vatanpour1Mina Amini2Majid Saeedi3Nasim Hafezi4Alireza Rafiei5Molecular and Cell Biology Research Center, Student Research Committee, Faculty of Medicine, Mazandaran University of Medical Science, Sari, IranMolecular and Cell Biology Research Center, Student Research Committee, Faculty of Medicine, Mazandaran University of Medical Science, Sari, IranFood and Drug Deputy, Mazandaran University of Medical Science, Sari, IranDepartments of Pharmaceutics and Medicinal Chemistry, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, IranDepartment of Immunology, School of Medicine, Mazandaran University of Medical Sciences, Sari, IranMolecular and Cell Biology Research Center, Student Research Committee, Faculty of Medicine, Mazandaran University of Medical Science, Sari, IranBackground. Monoclonal antibodies with high efficiency and specificity are one of the best strategies to diagnose and treat a variety of diseases such as cancer, autoimmunity, and inflammatory diseases. The market for monoclonal therapeutic antibodies (MTAs) has grown dramatically in the past decade. Objective. Given the importance of these issues, developing countries spend a high cost on importing or producing MTAs annually. This study intends to examine the market of monoclonal therapeutic antibodies in Iran and predict the future growth rate of this market using the obtained data. Methods. Data on the status of MTAs in the country (from 2008 to 2018) were obtained from the Food and Drug Deputy of Mazandaran University of Medical Sciences. The market status of MTAs was studied based on the dosage forms, application, and price. Then, the market outlook was predicted up to year 2025. Results. The results showed that 58.8% of all MTAs were humanized, and 86% of all antibody-based drugs were used to treat cancer. Sales of MTA-based medications will reach $454 million by 2025 and are projected to grow significantly in the future. Conclusion. Given the increasing technology of the production of MTAs and their use in targeted therapies worldwide, their consumption market in Iran is expected to grow significantly.http://dx.doi.org/10.1155/2021/5569590 |
| spellingShingle | Monireh Golpour Pouya Vatanpour Mina Amini Majid Saeedi Nasim Hafezi Alireza Rafiei The Perspective of Therapeutic Antibody Marketing in Iran: Trend and Estimation by 2025 Advances in Pharmacological and Pharmaceutical Sciences |
| title | The Perspective of Therapeutic Antibody Marketing in Iran: Trend and Estimation by 2025 |
| title_full | The Perspective of Therapeutic Antibody Marketing in Iran: Trend and Estimation by 2025 |
| title_fullStr | The Perspective of Therapeutic Antibody Marketing in Iran: Trend and Estimation by 2025 |
| title_full_unstemmed | The Perspective of Therapeutic Antibody Marketing in Iran: Trend and Estimation by 2025 |
| title_short | The Perspective of Therapeutic Antibody Marketing in Iran: Trend and Estimation by 2025 |
| title_sort | perspective of therapeutic antibody marketing in iran trend and estimation by 2025 |
| url | http://dx.doi.org/10.1155/2021/5569590 |
| work_keys_str_mv | AT monirehgolpour theperspectiveoftherapeuticantibodymarketinginirantrendandestimationby2025 AT pouyavatanpour theperspectiveoftherapeuticantibodymarketinginirantrendandestimationby2025 AT minaamini theperspectiveoftherapeuticantibodymarketinginirantrendandestimationby2025 AT majidsaeedi theperspectiveoftherapeuticantibodymarketinginirantrendandestimationby2025 AT nasimhafezi theperspectiveoftherapeuticantibodymarketinginirantrendandestimationby2025 AT alirezarafiei theperspectiveoftherapeuticantibodymarketinginirantrendandestimationby2025 AT monirehgolpour perspectiveoftherapeuticantibodymarketinginirantrendandestimationby2025 AT pouyavatanpour perspectiveoftherapeuticantibodymarketinginirantrendandestimationby2025 AT minaamini perspectiveoftherapeuticantibodymarketinginirantrendandestimationby2025 AT majidsaeedi perspectiveoftherapeuticantibodymarketinginirantrendandestimationby2025 AT nasimhafezi perspectiveoftherapeuticantibodymarketinginirantrendandestimationby2025 AT alirezarafiei perspectiveoftherapeuticantibodymarketinginirantrendandestimationby2025 |